148 related articles for article (PubMed ID: 36695492)
1. Arsenic-Loaded Biomimetic Iron Oxide Nanoparticles for Enhanced Ferroptosis-Inducing Therapy of Hepatocellular Carcinoma.
Liu J; Li X; Chen J; Zhang X; Guo J; Gu J; Mei C; Xiao Y; Peng C; Liu J; Hu X; Zhang K; Li D; Zhou B
ACS Appl Mater Interfaces; 2023 Feb; 15(5):6260-6273. PubMed ID: 36695492
[TBL] [Abstract][Full Text] [Related]
2. Albumin-Embellished Arsenic Trioxide-Loaded Polymeric Nanoparticles Enhance Tumor Accumulation and Anticancer Efficacy via Transcytosis for Hepatocellular Carcinoma Therapy.
Huang Y; Xu Z; Wei Y; Han S; Cai X; Chen D
AAPS PharmSciTech; 2022 Apr; 23(4):111. PubMed ID: 35411416
[TBL] [Abstract][Full Text] [Related]
3. ZnAs@SiO
Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
[No Abstract] [Full Text] [Related]
4. Nanocarrier-based delivery of arsenic trioxide for hepatocellular carcinoma therapy.
Sun J; Cheng M; Ye T; Li B; Wei Y; Zheng H; Zheng H; Zhou M; Piao JG; Li F
Nanomedicine (Lond); 2022 Nov; 17(26):2037-2054. PubMed ID: 36789952
[TBL] [Abstract][Full Text] [Related]
5. Delivery of Arsenic Trioxide by Multifunction Nanoparticles To Improve the Treatment of Hepatocellular Carcinoma.
Wu Q; Chen X; Wang P; Wu Q; Qi X; Han X; Chen L; Meng X; Xu K
ACS Appl Mater Interfaces; 2020 Feb; 12(7):8016-8029. PubMed ID: 31997633
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma.
Li X; Pan YF; Chen YB; Wan QQ; Lin YK; Shang TY; Xu MY; Jiang TY; Pei MM; Tan YX; Dong LW; Wan XY
Cell Death Dis; 2024 Apr; 15(4):300. PubMed ID: 38684648
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide-induced upregulation of miR-1294 suppresses tumor growth in hepatocellular carcinoma by targeting TEAD1 and PIM1.
Cai X; Yu L; Chen Z; Ye F; Ren Z; Jin P
Cancer Biomark; 2020; 28(2):221-230. PubMed ID: 32280078
[TBL] [Abstract][Full Text] [Related]
8. Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
Liu X; Zhu X; Qi X; Meng X; Xu K
Int J Nanomedicine; 2021; 16():1037-1050. PubMed ID: 33603367
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide inhibits angiogenesis of hepatocellular carcinoma after insufficient radiofrequency ablation via blocking paracrine angiopoietin-1 and angiopoietin-2.
Dong S; Li Z; Kong J; Wu S; Gao J; Sun W
Int J Hyperthermia; 2022; 39(1):888-896. PubMed ID: 35848416
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex.
Wang HY; Zhang B; Zhou JN; Wang DX; Xu YC; Zeng Q; Jia YL; Xi JF; Nan X; He LJ; Yue W; Pei XT
Cell Death Dis; 2019 Jun; 10(6):453. PubMed ID: 31186405
[TBL] [Abstract][Full Text] [Related]
11. pH-Responsive and liver-targeting drug delivery system for combination delivery of artesunate with arsenic trioxide prodrug against hepatocellular carcinoma.
Pan X; Huang J; Liu S; Shao Y; Xi J; He R; Shi T; Zhuang R; Yu W
Drug Dev Ind Pharm; 2023 Aug; 49(8):485-496. PubMed ID: 37470495
[TBL] [Abstract][Full Text] [Related]
12. Hypoxic Hepatocellular Carcinoma Cells Acquire Arsenic Trioxide Resistance by Upregulating HIF-1α Expression.
Chen Y; Li H; Chen D; Jiang X; Wang W; Li D; Shan H
Dig Dis Sci; 2022 Aug; 67(8):3806-3816. PubMed ID: 34383201
[TBL] [Abstract][Full Text] [Related]
13. Combination of canstatin and arsenic trioxide suppresses the development of hepatocellular carcinoma.
Zhang F; Duan J; Song H; Yang L; Zhou M; Wang X
Drug Dev Res; 2021 May; 82(3):430-439. PubMed ID: 33244794
[TBL] [Abstract][Full Text] [Related]
14. Shikonin potentiates the effect of arsenic trioxide against human hepatocellular carcinoma in vitro and in vivo.
Song J; Zhao Z; Fan X; Chen M; Cheng X; Zhang D; Wu F; Ying X; Ji J
Oncotarget; 2016 Oct; 7(43):70504-70515. PubMed ID: 27655700
[TBL] [Abstract][Full Text] [Related]
15. Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal.
Kong D; Jiang T; Liu J; Jiang X; Liu B; Lou C; Zhao B; Carroll SL; Feng G
Drug Deliv; 2020 Nov; 27(1):1729-1740. PubMed ID: 33307843
[TBL] [Abstract][Full Text] [Related]
16. Butyrate Modification Promotes Intestinal Absorption and Hepatic Cancer Cells Targeting of Ferroptosis Inducer Loaded Nanoparticle for Enhanced Hepatocellular Carcinoma Therapy.
Yu Y; Shen X; Xiao X; Li L; Huang Y
Small; 2023 Sep; 19(36):e2301149. PubMed ID: 37165608
[TBL] [Abstract][Full Text] [Related]
17. Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.
Zheng T; Yin D; Lu Z; Wang J; Li Y; Chen X; Liang Y; Song X; Qi S; Sun B; Xie C; Meng X; Pan S; Liu J; Jiang H; Liu L
Mol Cancer; 2014 May; 13():133. PubMed ID: 24884809
[TBL] [Abstract][Full Text] [Related]
18. Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma.
Chen A; Yu Z; Ma N; Lu X; Zhang Y; Xu W; Wang Y; Xie J; Qin Y; Mo G; Wu S; Hou J; Zhu W
Cancer Immunol Immunother; 2024 Feb; 73(3):49. PubMed ID: 38349553
[TBL] [Abstract][Full Text] [Related]
19. Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
Li W; Wang M; Wang L; Ji S; Zhang J; Zhang C
Cell Biochem Biophys; 2014 Mar; 68(2):427-36. PubMed ID: 23975599
[TBL] [Abstract][Full Text] [Related]
20. Low-density lipoprotein docosahexaenoic acid nanoparticles induce ferroptotic cell death in hepatocellular carcinoma.
Ou W; Mulik RS; Anwar A; McDonald JG; He X; Corbin IR
Free Radic Biol Med; 2017 Nov; 112():597-607. PubMed ID: 28893626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
